Q3 Earnings Forecast for Ardelyx Issued By Leerink Partnrs

Key Points

• Leerink Partners has increased its Q3 2025 earnings estimate for Ardelyx from ($0.12) to ($0.08) per share, reflecting a more optimistic outlook for the biopharmaceutical company.
• Ardelyx reported earnings of ($0.08) per share in its latest quarter, surpassing analysts' expectations of ($0.13), with revenues of $97.66 million compared to estimates of $82.69 million.
• Different analysts have mixed perspectives on Ardelyx, with one downgrading its rating to "sell", while others maintain "outperform" ratings with price targets ranging from $10.00 to $14.00.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at Leerink Partnrs increased their Q3 2025 EPS estimates for shares of Ardelyx in a report issued on Monday, August 4th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter, up from their prior estimate of ($0.12). The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Leerink Partnrs also issued estimates for Ardelyx's FY2025 earnings at ($0.37) EPS, FY2026 earnings at $0.28 EPS, FY2027 earnings at $0.95 EPS and FY2028 earnings at $1.76 EPS.

ARDX has been the subject of several other reports. Wall Street Zen upgraded Ardelyx from a "sell" rating to a "hold" rating in a report on Saturday. Citigroup cut their price target on Ardelyx from $11.00 to $10.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Piper Sandler boosted their price target on Ardelyx from $8.00 to $9.00 and gave the company a "neutral" rating in a report on Wednesday. HC Wainwright started coverage on Ardelyx in a report on Wednesday, June 18th. They issued a "buy" rating and a $10.00 price target for the company. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $12.00 price target (up from $11.00) on shares of Ardelyx in a report on Tuesday, August 5th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.50.

Ardelyx Price Performance

Shares of Ardelyx stock traded up $0.07 during trading on Thursday, hitting $5.21. 4,028,310 shares of the company were exchanged, compared to its average volume of 4,541,891. The company has a quick ratio of 3.81, a current ratio of 4.30 and a debt-to-equity ratio of 1.44. Ardelyx has a fifty-two week low of $3.21 and a fifty-two week high of $7.18. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -22.65 and a beta of 0.68. The firm has a 50 day moving average price of $4.16 and a 200 day moving average price of $4.63.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. Ardelyx had a negative return on equity of 36.57% and a negative net margin of 14.60%. The firm had revenue of $97.66 million during the quarter, compared to the consensus estimate of $82.69 million. During the same period in the previous year, the firm posted ($0.07) EPS. The company's quarterly revenue was up 23.0% compared to the same quarter last year.

Institutional Investors Weigh In On Ardelyx

Several institutional investors and hedge funds have recently bought and sold shares of the business. Ensign Peak Advisors Inc raised its stake in Ardelyx by 3.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 73,950 shares of the biopharmaceutical company's stock worth $375,000 after acquiring an additional 2,200 shares during the period. Savant Capital LLC raised its stake in Ardelyx by 7.1% during the second quarter. Savant Capital LLC now owns 39,386 shares of the biopharmaceutical company's stock worth $154,000 after acquiring an additional 2,610 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Ardelyx by 2.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 154,625 shares of the biopharmaceutical company's stock worth $788,000 after acquiring an additional 3,550 shares during the period. Crux Wealth Advisors raised its stake in Ardelyx by 17.7% during the second quarter. Crux Wealth Advisors now owns 27,393 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 4,120 shares during the period. Finally, Orion Portfolio Solutions LLC grew its position in Ardelyx by 42.7% in the 4th quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company's stock worth $84,000 after purchasing an additional 4,933 shares during the last quarter. Institutional investors and hedge funds own 58.92% of the company's stock.

Insider Transactions at Ardelyx

In other Ardelyx news, insider Laura A. Williams sold 6,421 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total value of $26,197.68. Following the transaction, the insider owned 402,583 shares in the company, valued at $1,642,538.64. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David M. Mott purchased 200,000 shares of Ardelyx stock in a transaction dated Monday, June 16th. The shares were bought at an average cost of $3.63 per share, for a total transaction of $726,000.00. Following the transaction, the director directly owned 2,896,871 shares of the company's stock, valued at approximately $10,515,641.73. The trade was a 7.42% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 500,000 shares of company stock worth $1,793,000 and have sold 83,477 shares worth $340,586. 4.80% of the stock is owned by corporate insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.